Indian contribution toward biomedical research and development in COVID-19: A systematic review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Medknow Publications Country of Publication: India NLM ID: 7902477 Publication Model: Print Cited Medium: Internet ISSN: 1998-3751 (Electronic) Linking ISSN: 02537613 NLM ISO Abbreviation: Indian J Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Mumbai : Medknow Publications
      Original Publication: Pondicherry, Published for the Indian Pharmacological Society by the Dept. of Pharmacology, Jawaharial Institute of Postgraduate Medical Education and Research, [1969?]-
    • Subject Terms:
      Biomedical Research* ; Drug Development* ; Drug Discovery* ; COVID-19 Drug Treatment*; Antiviral Agents/*therapeutic use ; COVID-19 Vaccines/*therapeutic use ; SARS-CoV-2/*drug effects; Animals ; Antiviral Agents/adverse effects ; Artificial Intelligence ; COVID-19/diagnosis ; COVID-19/virology ; COVID-19 Testing ; Clinical Trials as Topic ; Computer-Aided Design ; Diffusion of Innovation ; Drug Repositioning ; Humans ; India ; Predictive Value of Tests ; SARS-CoV-2/pathogenicity ; Treatment Outcome
    • Abstract:
      COVID-19 pandemic led to an unprecedented collaborative effort among industry, academia, regulatory bodies, and governments with huge financial investments. Scientists and researchers from India also left no stone unturned to find therapeutic and preventive measures against COVID-19. Indian pharmaceutical companies are one of the leading manufacturers of vaccine in the world, are utilizing its capacity to its maximum, and are one among the forerunners in vaccine research against COVID-19 across the globe. In this systematic review, the information regarding contribution of Indian scientists toward COVID-19 research has been gathered from various news articles across Google platform apart from searching PubMed, WHO site, COVID-19 vaccine tracker, CTRI, clinicaltrials.gov, and websites of pharmaceutical companies. The article summarizes and highlights the various therapeutic and vaccine candidates, diagnostic kits, treatment agents, and technology being developed and tested by Indian researcher community against COVID-19.
      Competing Interests: None
    • References:
      Indian J Med Res. 2020 Feb & Mar;151(2 & 3):200-209. (PMID: 32242873)
      Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. (PMID: 32700604)
      Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65. (PMID: 32201449)
      J Biomol Struct Dyn. 2022 Jul;40(10):4750-4765. (PMID: 33300456)
      J Med Virol. 2021 Mar;93(3):1538-1547. (PMID: 32881007)
      Indian J Pharmacol. 2020 Mar-Apr;52(2):142-149. (PMID: 32565603)
      Indian J Pharmacol. 2020 Jul-Aug;52(4):313-323. (PMID: 33078733)
      Cell. 2020 Oct 1;183(1):169-184.e13. (PMID: 32931734)
      Indian J Med Res. 2020 Feb & Mar;151(2 & 3):251-254. (PMID: 32242876)
      J Mol Graph Model. 2020 Dec;101:107716. (PMID: 32866780)
      J Biol Chem. 2021 Jan-Jun;296:100025. (PMID: 33154165)
      Open J Psychiatry Allied Sci. 2021 Jan-Jun;12(1):7-12. (PMID: 33163629)
      J Gen Intern Med. 2020 Nov;35(11):3308-3314. (PMID: 32885373)
      Med Hypotheses. 2021 Apr;149:110539. (PMID: 33662863)
      J Med Virol. 2020 Jul;92(7):776-785. (PMID: 32297988)
      Graefes Arch Clin Exp Ophthalmol. 2020 Nov;258(11):2563-2565. (PMID: 32436084)
      Diabetes Metab Syndr. 2020 Sep - Oct;14(5):757-759. (PMID: 32504992)
      Molecules. 2020 Nov 02;25(21):. (PMID: 33147850)
      Indian J Pharmacol. 2020 Nov-Dec;52(6):535-550. (PMID: 33666200)
      Front Immunol. 2020 May 15;11:1061. (PMID: 32574262)
      Pharmacol Rep. 2021 Jun;73(3):736-749. (PMID: 33389725)
      Asian J Psychiatr. 2020 Oct;53:102227. (PMID: 32574942)
      Ann Intern Med. 2021 Mar;174(3):434. (PMID: 33721533)
      mSystems. 2020 Sep 22;5(5):. (PMID: 32963099)
      Comput Struct Biotechnol J. 2020;18:3734-3744. (PMID: 33200027)
      Nature. 2021 Feb;590(7845):194-195. (PMID: 33536600)
      Heart Lung. 2021 Jan - Feb;50(1):9-12. (PMID: 33041057)
      J Biomol Struct Dyn. 2021 May;39(8):2724-2732. (PMID: 32266867)
      Sci Rep. 2021 Jun 18;11(1):12888. (PMID: 34145351)
      Int J Biol Macromol. 2021 Feb 28;171:358-365. (PMID: 33421473)
      Tissue Cell. 2021 Jun;70:101497. (PMID: 33550034)
      J Biomol Struct Dyn. 2021 Oct;39(17):6617-6632. (PMID: 32715956)
      Hepatol Int. 2020 Sep;14(5):711-722. (PMID: 32623633)
      Virusdisease. 2020 Dec;31(4):453-458. (PMID: 33283030)
      Indian J Pharmacol. 2020 Sep-Oct;52(5):414-421. (PMID: 33283773)
      Indian J Med Res. 2020 May;151(5):419-423. (PMID: 32611913)
      PLoS Biol. 2021 Feb 25;19(2):e3001091. (PMID: 33630831)
      Front Genet. 2021 Mar 19;12:586569. (PMID: 33815459)
      Methods. 2021 Nov;195:57-71. (PMID: 33453392)
      J Med Virol. 2021 Feb;93(2):1111-1118. (PMID: 32776573)
      Lancet Glob Health. 2021 Mar;9(3):e257-e266. (PMID: 33515512)
      J Biomol Struct Dyn. 2022 Feb;40(3):963-970. (PMID: 32930058)
      Front Pharmacol. 2021 Jan 14;11:579330. (PMID: 33568991)
      Heliyon. 2020 Oct;6(10):e05122. (PMID: 33020742)
      Indian J Public Health. 2020 Jun;64(Supplement):S231-S233. (PMID: 32496262)
      Graefes Arch Clin Exp Ophthalmol. 2020 Nov;258(11):2575-2578. (PMID: 32725405)
      Open J Psychiatry Allied Sci. 2021 Jan;12(1):31-35. (PMID: 33123627)
    • Contributed Indexing:
      Keywords: AYUSH; Artificial intelligence; COVID-19; India; SARS-CoV2; clinical trials; drug designing; vaccine
    • Accession Number:
      0 (Antiviral Agents)
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20210512 Date Completed: 20210519 Latest Revision: 20231107
    • Publication Date:
      20240829
    • Accession Number:
      PMC8216129
    • Accession Number:
      10.4103/ijp.ijp_168_21
    • Accession Number:
      33976001